CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Gilead Sciences, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Gilead Sciences, Inc.
333 Lakeside Drive
Phone: (650) 574-3000p:650 574-3000 FOSTER CITY, CA  94404  United States Ticker: GILDGILD

Business Summary
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-YesYes--

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes-YesYes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer DanielO'Day 58 3/1/2019 3/1/2019
Chief Financial Officer Andrew D.Dickinson 53 1/1/2020 6/4/2018
Executive Vice President - Corporate Affairs, General Counsel, Corporate Secretary Deborah H.Telman 58 8/1/2022 8/1/2022
9 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Gilead Alberta ULC 1021 Hayter Road Edmonton AB Canada
Forty Seven, Inc. 1490 Obrien Dr Menlo Park CA United States
CymaBay Therapeutics Inc SUITE 130, 7999 GATEWAY BLVD NEWARK CA United States
10 additional Subsidiary records available in full report.

Business Names
Business Name
Asegua Therapeutics LLC
CymaBay Therapeutics, Inc.
Cytopia Pty. Ltd.
76 additional Business Names available in full report.

General Information
Number of Employees: 18,000 (As of 12/31/2023)
Outstanding Shares: 1,245,774,616 (As of 2/16/2024)
Shareholders: 1,396
Stock Exchange: NASD
Federal Tax Id: 943047598
Fax Number: (650) 578-9264
Email Address: corporate_communications@gilead.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024